Recent research have focused on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GIP agonists are widely employed for treating type 2 diabetes mellitus, their emerging effects on motivation circu